CoChat

PARP inhibitors: the race is on

Open access
Brown, Jessica S, Kaye, Stan B, Yap, Timothy A · 2016 · British Journal of Cancer
Cited by 147

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Since the seminal publications in 2005 that demonstrated the exquisite sensitivity of BRCA1 and BRCA2 ( BRCA1/2 ) mutant cell lines and xenografts to poly(ADP-ribose) polymerase (PARP) inhibition ( Bryant et al, 2005 ; Farmer et al, 2005 ), the race has been on to exploit single-agent PARP inhibitors for clinical use through the concept of tumour-specific synthetic lethality ( Yap et al., 2011 ; O’Connor, 2015 ). In 2014, olaparib (Lynparza; AstraZeneca, London, UK) was the first PARP inhibitor to be approved by the European Medicines Agency as maintenance therapy for responding patients with BRCA1/2 mutant ovarian cancer following platinum-based chemotherapy, and the first to obtain accelerated approval by the US Food and Drug Administration (FDA) for advanced BRCA1/2 mutant ovarian cancer while confirmatory trials are completed. There are, however, several other potent and bona fide PARP inhibitors, including rucaparib (AGO14699; Clovis, Boulder, CO, USA), niraparib (MK4827; Tesaro, Waltham, MA, USA), talazoparib (BMN-673; Medivation, San Francisco, CA, USA) and veliparib (ABT-888; Abbvie, North Chicago, IL, USA), which are all currently in late phase clinical trial development ( Table 1 ). Rucaparib was granted breakthrough therapy designation by the FDA in April 2015, following the results of the ARIEL2 trial ( Kristeleit et al., 2015 ) for use as monotherapy in patients with BRCA1/2 mutant (germline or somatic) advanced ovarian cancer after at least two prior lines of platinum-containing therapy. Table 1 Table showing the response rates and predominant toxicities for different PARP inhibitors in patients with advanced ovarian cancer Full size table

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.2016.67

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 147

Metadata

Authors
Brown, J. S., Kaye, S. B., & Yap, T. A.
Venue
British Journal of Cancer
Published
2016-03
Volume
114
Issue
7
Pages
713-715
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2318905487
Cited by
147
References
6
FWCI
13.13
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.